Go To Global Site
Welcome to UCB in the United States

Dec

06

Press Release: Bimekizumab Phase 3 Psoriasis Study Demonstrates Superiority Versus Humira®

Bimekizumab Phase 3 Psoriasis Study Demonstrates Superiority Versus Humira®

Dec

05

Press Release: UCB Presents New Data Demonstrating Commitment to Epilepsy at 2019 American Epilepsy Society Meeting

• 14 scientific presentations will cover UCB’s pipeline assets, epilepsy-specific research, and licensed medicines, including NAYZILAM, now available for the acute treatment of seizure clusters in epilepsy patients 12 years of age and older
• Friday evening symposium on “Epilepsy Treatment Update for Patients Suffering from Seizure Clusters” includes Epilepsy Foundation’s project on seizure emergencies and a panel discussion on the misconceptions around seizure clusters

Dec

04

Spencer’s Story: What to Know About Seizure Clusters

At just one day old, Spencer, born in Greenville, South Carolina, had his first seizure, a sudden, uncontrolled electrical disturbance in the brain that usually causes a change in behavior.1,2

Nov

25

Press Release: UCB Announces availability of NAYZILAM® (midazolam) Nasal Spray CIV, the first and only nasal rescue treatment for seizure clusters in the U.S.

• NAYZILAM will be available in retail pharmacies on December 2, 2019
• Copay support and a patient assistance program will be provided by UCB for eligible NAYZILAM patients*

Nov

15

Press Release: Bimekizumab Positive Results Confirmed in Second Phase 3 Psoriasis Study

• The Phase 3 BE READY study, evaluating the efficacy and safety of bimekizumab versus placebo in adults with moderate-to-severe chronic plaque psoriasis, met all primary and ranked secondary endpoints1
• UCB plans to submit applications to regulatory authorities for approval of bimekizumab to treat adults with moderate-to-severe plaque psoriasis in mid-2020

Nov

08

Press Release: UCB Presents New Data From Rheumatology Portfolio Addressing Unmet Needs in Axial Spondyloarthritis, Psoriatic Arthritis and Lupus at 2019 ACR/ARP

UCB Presents New Data From Rheumatology Portfolio Addressing Unmet Needs in Axial Spondyloarthritis, Psoriatic Arthritis and Lupus at 2019 ACR/ARP

Nov

06

What You See Is What You Get

UCB's Denelle Waynick, VP, Legal Affairs (U.S.), U.S. General Counsel and Global Head, Enterprise Risk Management, leads by example by being true to herself to encourage others to do so too. Read more from Denelle on why by being authentic to yourself, you become stronger as an individual, leader, and employee. Read the full article on LinkedIn.

Oct

30

Patients Inspiring Growth at UCB's Bedford Lab

UCB researchers like Jessica Williamson, PhD, come to work driven by a singular purpose – to create value for people living with severe disease. That’s because patients depend on the important work of scientific research to discover new medical innovations that will help them achieve their goals. Read more from Dr. Williamson about why she's passionate about innovating for patients and UCB's growing research presence in the greater Boston area.

Oct

21

Infographic: Seizure Clusters

At UCB, we keep patients at the center - inspiring us, driving our scientific discovery, and leading us to rethink the patient experience. We have a rich heritage in epilepsy, and today, we’re shining a spotlight on seizure clusters, which can affect people with uncontrolled epilepsy, to help spread awareness. Check out the full infographic below.

Oct

21

Disease Spotlight: Seizure Clusters

At UCB, we keep patients at the center - inspiring us, driving our scientific discovery, and leading us to rethink the patient experience. We have a rich heritage in epilepsy, and today, we’re shining a spotlight on seizure clusters, which can affect people with uncontrolled epilepsy, to help spread awareness.